Analysis Tools
hematopoietic system
| N |
• hematopoietic stem cell numbers are similar to controls at 6-8 weeks of age and cells perform similar to control cells in a competitive transplantation assay
|
|
Allele Symbol Allele Name Allele ID |
Pkn3tm1.1Mrl targeted mutation 1.1, Merck Research Laboratory MGI:5688854 |
||||||||||||||||||||||||
| Summary |
5 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• hematopoietic stem cell numbers are similar to controls at 6-8 weeks of age and cells perform similar to control cells in a competitive transplantation assay
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• thymus weight is similar to controls at 6-8 weeks of age unlike in mutant mice wild-type for Pkn3
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• lifespan after pIpC treatment is shorter than in controls but longer than in mutant nice with one wild-type Pkn3 allele
|
|
• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment
|
|
• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age
|
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
|
• at 2 weeks after pIpC treatment
|
|
• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
|
• at 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• lifespan after pIpC treatment is shorter than in controls and in mutant nice with no wild-type Pkn3 alleles
|
|
• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment
|
|
• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age
|
|
• at 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
• at 2 weeks after pIpC treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• peripheral and bone marrow hematopoietic cell counts are similar to controls at 8 weeks after pIpC treatment
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 05/07/2024 MGI 6.23 |
|
|
|
||